Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
Chemotherapy treatment of malignancy accounts for 1–2% of takotsubo syndrome (TS) triggers. Women comprise 60–70% of patients with chemotherapy-associated TS, a distinctly lower prevalence than the 90% female prevalence in TS overall. Fluorouracil is the most commonly reported TS-triggering chemothe...
Enregistré dans:
Auteurs principaux: | Katelyn Storey, Scott W Sharkey |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Radcliffe Medical Media
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/2ca97b83a2134bdabf38af4fc13a2ed4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Diagnosis of Takotsubo syndrome in the COVID-19 era
par: Kristian Rivera, et autres
Publié: (2021) -
Diagnosis of Takotsubo syndrome in the COVID-19 era
par: Kristian Rivera, et autres
Publié: (2021) -
Novel Aspects of Classification, Prognosis and Therapy in Takotsubo Syndrome
par: Chiara Di Filippo, et autres
Publié: (2019) -
Takotsubo Syndrome During the COVID-19 Pandemic: State-of-the-Art Review
par: Gassan Moady, MD, et autres
Publié: (2021) -
Takotsubo syndrome early after treatment due to non cardiotoxic chemotherapy agents
par: Benay Özbay, et autres
Publié: (2021)